Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07614776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Name: A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration — clinical trial record (NCT07614776)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2026-05-27

View on ClinicalTrials.gov ↗

The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)

Amendment history 5 changes detected by DataLookout

2026-08-18

Trial sites expanded: 36 → 51 locations

2026-07-29

Trial sites expanded: 29 → 36 locations

2026-07-07

Trial sites expanded: 20 → 27 locations

2026-06-13

Recruitment opened

2026-06-13

Trial sites expanded: 0 → 18 locations

Trial Details

NCT Number	NCT07614776
Lead Sponsor	Amgen
Conditions	Neovascular Age-related Macular Degeneration, nAMD
Enrollment	304 participants
Start Date	2026-05-27
Primary Completion	2027-07-31 (estimated)
Study Completion	2028-01-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-24